Immune activation, smoking, and vaccine response

Mehwish Younas (1) , Fabrice Carrat (2, 3) , Corinne Desaint (4, 5, 6, 7, 8, 9) , Odile Launay (4, 5, 6, 7, 8, 9) , Pierre Corbeau (1, 10)

1 IGH - Institut de génétique humaine
2 iPLESP - Institut Pierre Louis d'Epidémiologie et de Santé Publique
3 CHU Saint-Antoine [AP-HP]
4 CIC 1417 - CIC Cochin Pasteur
5 REIVAC - REseau national d'Investigation clinique en VACcinologie
6 USPC - Université Sorbonne Paris Cité
7 AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP)
8 Hôpital Cochin [AP-HP]
9 UPD5 - Université Paris Descartes - Paris 5
10 CHU Nîmes - Centre Hospitalier Universitaire de Nîmes

Here, we tested the hypothesis that chronic immune activation might fuel interindividual variability in vaccine response in the model of hepatitis B virus vaccine in HIV-1-infected adults. We observed that the marker of inflammation soluble tumour necrosis factor receptor I (sTNFRI) is predictive for vaccine efficiency. We also established that the link between tobacco smoking and impaired vaccine response might be mediated by inflammation. These data are a step forward in personalized vaccination.

Domaines: Maladies infectieuses; Immunologie; Virologie

Mehwish Younas, Fabrice Carrat, Corinne Desaint, Odile Launay, Pierre Corbeau. Immune activation, smoking, and vaccine response. AIDS. Official journal of the international AIDS Society, 2017, 31 (1), pp.171 - 173. ⟨10.1097/QAD.0000000000001311⟩. ⟨hal-01900458⟩